EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer

Tsuyoshi Hirata iD, Kageaki Watanabe iD, Yukio Hosomi, Kiyotaka Yoh, Kazuhiro Usui, Kazuma Kishi, Go Naka, Shu Tamano, Kohei Uemura, Hideo Kunitoh

Japanese Journal of Clinical Oncology · 2025

DOI: 10.1093/jjco/hyae176 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Japanese Journal of Clinical Oncology, 2025. Verfasst von Tsuyoshi Hirata und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22, Honko…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Aniline Compounds, Acrylamides. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Osimertinib, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, is a first-line therapy for advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations, including both sensitizing and T790M resistance mutations. Its real-world efficacy against uncommon EGFR mutations remains under-researched.

Methods

The REIWA study, a multicentric, prospective, observational study conducted in Japan from September 2018 to August 2020, enrolled patients with advanced or recurrent EGFR mutation-positive NSCLC receiving osimertinib. Data on clinical outcomes, safety, disease progression, and subsequent treatments were collected for patients with uncommon EGFR mutations.

Results

Of 583 patients receiving osimertinib, 39 (6.7%) had an uncommon EGFR mutation. The present study included 32 of these patients after excluding seven patients with an exon 20 insertion mutation. The overall objective response rate was 53.1% [95% confidence interval (CI): 36.4–69.1], and the disease control rate was 78.1% (95% CI: 61.0–89.3). The median progression-free survival was 9.4 months (95% CI: 5.0–20.0), and the median overall survival (OS) was 21.8 (95% CI: 14.4–NA) months. Notably, patients with an exon21 L861Q mutation had a significantly longer OS than those with an exon18 G719X mutation, the respective values being 37.8 and 9.7 months (hazard ratio: 0.29; 95% CI: 0.10–0.85; P = 0.02). The rate of grade 3 or worse adverse events was 10.3%. Seven out of 32 (21.9%) patients showed progression involving only the central nervous system.

Conclusions

Osimertinib demonstrated efficacy and tolerability in the clinical setting in patients with uncommon EGFR mutation-positive NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsAniline CompoundsAcrylamidesProtein Kinase InhibitorsAntineoplastic AgentsHumansMaleFemaleAgedErbB ReceptorsMiddle AgedMutationProspective StudiesAged, 80 and overAdultIndolesPyrimidines

Stichwörter der Autor:innen

Osimertinibnon-small cell lung cancerobservational studyuncommon epidermal growth factor receptor-activating mutation

Substanzen

osimertinibAniline CompoundsAcrylamidesErbB ReceptorsEGFR protein, humanProtein Kinase InhibitorsAntineoplastic AgentsIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Thoracic Oncology and Respiratory Medicine, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo 113-8677, Japan.
  • Department of Thoracic Oncology, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, Chiba 277-8577, Japan.
  • Department of Respiratory Medicine, NTT Medical Center Tokyo, 5-9-22, Higashigotanda, Shinagawa-ku, Tokyo 141-0022, Japan.
  • Department of Respiratory Medicine, Toho University Omori Medical Center, 6-11-1, Ohmorinishi, Ota-ku, Tokyo 143-8541, Japan.
  • Department of Respiratory Medicine, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo 162-8655, Japan.
  • Division of Respiratory Medicine, Department of Internal Medicine, Nihon University School of Medicine, 1-6, Kandasurugadai, Chiyoda-ku, Tokyo 101-8309, Japan.

ORCID-Profile: Tsuyoshi Hirata, Kageaki Watanabe

Zitieren

APA

Hirata, T., Watanabe, K., Hosomi, Y., Yoh, K., Usui, K., Kishi, K., Naka, G., Tamano, S., Uemura, K., & Kunitoh, H. (2025). Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer. Japanese Journal of Clinical Oncology. https://doi.org/10.1093/jjco/hyae176

Vancouver

Hirata T, Watanabe K, Hosomi Y, Yoh K, Usui K, Kishi K, et al. Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer. Japanese Journal of Clinical Oncology. 2025. doi:10.1093/jjco/hyae176

BibTeX
@article{Hirata2025,
  author = {Hirata, Tsuyoshi and Watanabe, Kageaki and Hosomi, Yukio and Yoh, Kiyotaka and Usui, Kazuhiro and Kishi, Kazuma and Naka, Go and Tamano, Shu and Uemura, Kohei and Kunitoh, Hideo},
  title = {Observational study of the efficacy and safety of first-line osimertinib and later treatments for uncommon epidermal growth factor receptor-activating mutation-positive advanced non-small cell lung cancer},
  journal = {Japanese Journal of Clinical Oncology},
  year = {2025},
  doi = {10.1093/jjco/hyae176}
}
Kostenlos starten →